Safety

Large cohort links GLP-1 drugs to more diabetic retinopathy, not to vision loss

by
GLP-1 drugs, diabetic retinopathy and what 98,082 pairs showed

A large propensity-matched cohort study published in Diabetes, Obesity and Metabolism on 27 August 2026 found that people who started a GLP-1 receptor agonist were modestly more likely to be diagnosed with diabetic retinopathy, and more likely to undergo a retinopathy procedure, than matched people who started a DPP-4 inhibitor instead. The same study found … Read more

FDA warns BioDrive over its “GLP-1 biomimetic” peptide supplement

by
FDA warning letter to BioDrive over its Evolv GLP-1 Biomimetic peptide supplement

On 24 August 2026 the US Food and Drug Administration issued a warning letter to BioDrive, Inc. over Evolv GLP-1 Biomimetic, a dietary supplement whose labeling declares “Saccharomyces cerevisiae S288C EV-1 Peptide” as a dietary ingredient. FDA classed that ingredient as a new dietary ingredient and found the product adulterated under section 402(f)(1)(B) of the … Read more